Safety of Besivance™ (Besifloxacin Ophthalmic Suspension) 0.6% Compared to Vehicle

Inclusion Criteria:

• Subjects must have a clinical diagnosis of acute bacterial conjunctivitis and exhibitpurulent conjunctival discharge (crusty or sticky eyelids) and redness in at least oneeye.

• Subjects who are willing to discontinue contact lens wear for the duration of thestudy.

• Subjects who are able and willing to comply with all treatment and follow- up/studyprocedures.

Exclusion Criteria:

• Subjects who have any uncontrolled systemic disease or debilitating disease.

• Subjects with a known hypersensitivity or contraindications to Besivance,fluoroquinolones, or any of the ingredients in the study drugs.

• Subjects who are expected to require disallowed concurrent systemic or oculartherapy(either eye)during or prior to study start. (ie, NSAIDs, corticosteroids, mastcell stabilizers, antihistamines, decongestants or antimicrobial therapy)

• Subjects having ocular surgery (including laser surgery) in either eye within sixweeks prior to entry into this study.

• Subjects with suspected viral or allergic conjunctivitis or any other diseaseconditions that could interfere with the efficacy and safety evaluations of the studymedication.

• Subjects with suspected iritis.

• Subjects with a history of recurrent corneal erosion syndrome, either idiopathic orsecondary to previous corneal trauma or dry eye syndrome.

• Subjects with any active ulcerative keratitis, specifically any epithelial lossgreater than punctate keratitis.

• Subjects who are immune compromised.